RT Journal Article
SR Electronic
T1 Distinct microRNA expression signatures of primary and secondary central nervous system lymphomas
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.02.05.21249862
DO 10.1101/2021.02.05.21249862
A1 Endre Sebestyén
A1 Ákos Nagy
A1 Dóra Marosvári
A1 Hajnalka Rajnai
A1 Béla Kajtár
A1 Beáta Deák
A1 András Matolcsy
A1 Sebastian Brandner
A1 James Storhoff
A1 Ning Chen
A1 Attila G. Bagó
A1 Csaba Bödör
A1 Lilla Reiniger
YR 2021
UL http://medrxiv.org/content/early/2021/02/08/2021.02.05.21249862.abstract
AB Central nervous system (CNS) lymphoma is a rare and aggressive non-Hodgkin lymphoma that might arise in the CNS (primary CNS lymphoma, PCNSL) or disseminates from a systemic lymphoma to the CNS (secondary CNS lymphoma, SCNSL). Dysregulated expression of microRNAs (miRNAs) is associated with various pathological processes and miRNA expression patterns may have diagnostic, prognostic and therapeutic implications. However, miRNA expression is understudied in CNS lymphomas. Here, we performed expression analysis of 798 miRNAs in 73 CNS lymphoma samples using the NanoString platform, followed by a detailed statistical analysis to identify potential novel biomarkers characterizing subgroups and to examine differences based on their primary and secondary nature, molecular subtype, mutational patterns and survival. We describe the general expression patterns of miRNAs across CNS lymphoma samples and identified 31 differentially expressed miRNAs between primary and secondary groups. Additionally, we identified 7 more miRNAs associated with a molecular subtype and 25 associated with mutation status. Using unsupervised clustering methods, we defined a small but distinct primary CNS lymphoma subgroup, with characteristically different expression patterns compared to the rest of the cases. Finally, we identified differentially regulated pathways in the above comparisons and assessed the utility of miRNA expression patterns in predicting survival. Our study identifies a novel CNS lymphoma subgroup defined by distinct miRNAs, proves the importance of specific miRNAs and pathways in their pathogenesis, and provides the basis for future research.Competing Interest StatementThe authors declare the following competing interest. James Storhoff and Ning Chen were employees of NanoString Technologies when the original NanoString analyses were carried out. James Storhoff is currently an employee of Veracyte. Ning Chen is currently an employee of Adaptive Biotechnologies.Funding StatementThis work was funded by the Hungarian Science Foundation (OTKA-PD115792 to LR) and Hungarian National Research, Development and Innovation Office (NKFIH) (KH17-126718 to CsB, NVKP_16-1-2016-0004 to AM and FK-132666 to ES). Furthermore, the study was supported by the Higher Education Institutional Excellence Programme of the Ministry of Human Capacities in Hungary within the framework of the Molecular Biology thematic programme of the Semmelweis University to CsB, the Hungarian Brain Research Program (2017-1.2.1-NKP-2017-00002 to LR), Semmelweis University Science and Innovation Fund (STIA_18_KF to ES and STIA_21_KF to CsB), Elixir Hungary (to CsB) and the Research Grant of the University of Pecs Medical School (KA-2019-32 to BK). The UK Brain Archive Information Network (BRAIN UK) is funded by the Medical Research Council and Brain Tumour Research. Sebastian Brandner was partly supported by the National Institute for Health Research Biomedical Research Centre's funding scheme to UCLH.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study ethics was approved by the Semmelweis University Regional and Institutional Committee of Science and Research Ethics. On 2012-10-31 the Committee ruled that archived patient samples can be used for research without additional ethics approval, if the research aims to improve molecular diagnostics methods (TUKEB 155/2012). The study ethics was also approved by BRAIN UK on 2016-10-21 (Ref.: 16/018). The study was conducted in accordance with the 1964 Helsinki declaration. All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived. TUKEB: Medical Research Council, Mailing address: 7-8 Szechenyi Istvan ter, Budapest, H-1051, Hungary, website: https://ett.aeek.hu/en/secretariat/ BRAIN UK: University of Southampton, University Road, Southampton SO17 1BJ, UK, website: https://www.southampton.ac.uk/brainuk/index.page?All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe datasets supporting the conclusions of this article are included within the article, its additional files and at the NCBI GEO database with accession number GSE162956.